Nkarta to Participate in March 2026 Investor Conferences

Got story updates? Submit your updates here. ›

Nkarta, Inc., a clinical-stage biopharmaceutical company focused on developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, has announced its participation in two upcoming investor conferences in March 2026.

Why it matters

Nkarta's participation in these high-profile investor conferences signals the company's progress in advancing its pipeline of NK cell therapies, which have the potential to provide new treatment options for patients with autoimmune conditions.

The details

Nkarta will present at the TD Cowen 46th Annual Health Care Conference in Boston on March 2, 2026, and the Leerink Global Healthcare Conference in Miami on March 10, 2026. The company will provide updates on its clinical development programs and technology platform during fireside chat presentations at both events.

• Nkarta will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 at 9:10 a.m. EST.
• Nkarta will present at the Leerink Global Healthcare Conference on March 10, 2026 at 10:40 a.m. EDT.

What’s next

Investors and the public will be able to access live webcasts of Nkarta's presentations, and replays will be available on the company's website for approximately 90 days.